ArticleISRN microbiology2012
Candida albicans: A Model Organism for Studying Fungal Pathogens.
Article in ISRN microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 147 citations in OpenAlex.
- High-Wavenumber Raman Spectroscopy for the Identification and Biochemical Characterization of Microbial Species.Analytical chemistry · 2025Article
- Mss2 shapes the virulence ofVirulence · 2025Article
- Article
- Clinical Characteristics and In Vivo Confocal Microscopic Study in Candida Keratitis.Translational vision science & technology · 2025Article
- Research advances and public health strategies in China on WHO priority fungal pathogens.Mycology · 2025Review
- Genomics insights of candidiasis: mechanisms of pathogenicity and drug resistance.Frontiers in microbiology · 2025Review
- Gain- and loss-of-function alleles within signaling pathways lead to phenotypic diversity among individuals.iScience · 2024Article
- Mitigating candidiasis with acarbose by targeting Candida albicans α-glucosidase: in-silico, in-vitro and transcriptomic approaches.Scientific reports · 2024Article
- Central Carbon Metabolism inJournal of fungi (Basel, Switzerland) · 2024Article
- Suillus: an emerging model for the study of ectomycorrhizal ecology and evolution.The New phytologist · 2024Review
- Monitoring ofCurrent medical mycology · 2024Article
- Preparation and characterization of a curcumin nanoemulsion gel for the effective treatment of mycoses.Scientific reports · 2023Article
- Phytochemical analysis and antibacterial/antifungal activity of the essential oil of Phlomis olivieri Benth in Iran.Inflammopharmacology · 2023Article
- Identification of potent anti-Candida metabolites produced by the soft coral associated Streptomyces sp. HC14 using chemoinformatics.Scientific reports · 2023Article
- Functional Clustering of Metabolically Related Genes Is Conserved acrossJournal of fungi (Basel, Switzerland) · 2023Review
- Antimicrobial Performance of Innovative Functionalized Surfaces Based on Enamel Coatings: The Effect of Silver-Based Additives on the Antibacterial and Antifungal Activity.International journal of molecular sciences · 2023Article
- Is There a Relationship Between Mating and Pathogenesis in Two Human Fungal Pathogens,Current clinical microbiology reports · 2023Review
- Inhibitory effect of lactobacilli supernatants on biofilm and filamentation ofFrontiers in microbiology · 2023Article
- Role ofPathophysiology : the official journal of the International Society for Pathophysiology · 2022Review
- Candidacidal and Antibiofilm Activity of PS1-3 Peptide against Drug-ResistantPharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Candida albicans is an opportunistic human fungal pathogen that causes candidiasis. As healthcare has been improved worldwide, the number of immunocompromised patients has been increased to a greater extent and they are highly susceptible to various pathogenic microbes and C. albicans has been prominent among the fungal pathogens. The complete genome sequence of this pathogen is now available and has been extremely useful for the identification of repertoire of genes present in this pathogen. The major challenge is now to assign the functions to these genes of which 13% are specific to C. albicans. Due to its close relationship with yeast Saccharomyces cerevisiae, an edge over other fungal pathogens because most of the technologies can be directly transferred to C. albicans from S. cerevisiae and it is amenable to mutation, gene disruption, and transformation. The last two decades have witnessed enormous amount of research activities on this pathogen that leads to the understanding of host-parasite interaction, infections, and disease propagation. Clearly, C. albicans has emerged as a model organism for studying fungal pathogens along with other two fungi Aspergillus fumigatus and Cryptococcus neoformans. Understanding its complete life style of C. albicans will undoubtedly be useful for developing potential antifungal drugs and tackling Candida infections. This will also shed light on the functioning of other fungal pathogens.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.